About BillionToOne
BillionToOne is a next-generation molecular diagnostics company headquartered in Menlo Park, California, with a mission to create powerful and accurate tests that are accessible to all. The company has developed a proprietary Quantitative Counting Templates (QCT™) platform that powers its single-molecule next-generation sequencing (smNGS) technology, enabling direct measurement of sparse disease-causing DNA fragments at the single base-pair level. The company operates in two primary areas: prenatal screening and oncology. In prenatal care, Unity Complete® is the first non-invasive prenatal test (NIPT) that uses cell-free DNA to assess fetal risk for recessive conditions and aneuploidy from a single maternal blood sample as early as 9 weeks, identifying approximately 3x more affected pregnancies than traditional screening without requiring a partner sample. The Unity platform has expanded to include Unity Confirm™, Unity Expanded Red Blood Cell, and Platelet Fetal Antigen NIPTs. In oncology, BillionToOne offers the Northstar platform, which includes Northstar Select® for therapy selection and Northstar Response® for treatment monitoring. Northstar Select is demonstrated to uncover approximately 50% more clinically actionable alterations than other ctDNA tests in head-to-head studies. The platform has been expanded with Northstar PGx™ for pharmacogenomic insights and Northstar Select CH™ for clonal hematopoiesis detection. The company's technology enables tracking of tumor burden changes down to 0.01% tumor fraction without requiring tissue samples. Founded by co-founders Oguzhan Atay, PhD, and David Tsao, PhD, BillionToOne operates CLIA-certified and CAP-accredited laboratories in Union City and Menlo Park, California. The company has established partnerships with major healthcare systems through Epic EMR integration and collaborates with leading research institutions including the National Cancer Center Hospital East in Japan.
Mission & Story
Mission
To create powerful and accurate tests that are accessible to all
Founding Story
Co-founded by Oguzhan Atay, PhD, and David Tsao, PhD, along with a team of scientists, engineers, and industry experts who care deeply about every sample that comes into their lab
Clinical Focus
Medical conditions and clinical areas addressed by BillionToOne.
Who It Serves
Milestones & Awards
Recent Milestones
Q1 2026 revenue guidance raised; Unity Confirm™ launched May 2026; Northstar PGx and Northstar Select CH launched February 2026; Unity Expanded RBC and Platelet Fetal Antigen NIPTs launched February 2026; Epic collaboration announced January 2026; Northstar Select selected for LC-SCRUM-TRY study January 2026
Key Partnerships
Social & Media
Follow on
Company Details
- Headquarters
- Menlo Park, CA, USA
Work here?
Claim this listing to update company information and connect with our audience.
Claim This ListingSecurity & Compliance
Official Sources
Similar Companies in this Market
View all 60 →
23andMe
23andMe uses AI to analyze genetic data and provide personalized health summaries, risk assessments, and wellness recommendations based on genomic insights.
2bPrecise
AI-powered precision medicine platform for personalized treatment recommendations and genomic analysis.
ACT Genomics
AI-powered genomic analysis platform for precision medicine and personalized treatment recommendations.
Adaptive Biotechnologies
Adaptive Biotechnologies uses AI and machine learning to decode the immune system and identify disease-specific immune signatures for diagnosis and personalized treatment.
Ambry Genetics
Ambry Genetics is a leading clinical genetic testing laboratory specializing in hereditary cancer, rare disease, cardiology, and neurology testing. The company provides advanced genetic testing solutions with paired DNA/RNA analysis and comprehensive patient support programs.
Ataraxis
Ataraxis develops AI-native precision medicine tools that predict patient outcomes and treatment response in oncology. Their flagship product, Ataraxis Breast, provides clinically validated prognostic and predictive tests for breast cancer using multi-modal AI analysis of pathology images and clinical data.
Avenda Health
Avenda Health develops Unfold AI, an FDA-cleared artificial intelligence platform that creates 3D cancer estimation maps for prostate cancer. The technology analyzes standard-of-care data (MRI, biopsy, pathology, PSA) to visualize cancer location and extent, helping physicians make more informed treatment decisions and improve patient outcomes.
Base Genomics
Base Genomics appears to be a company in the Precision Medicine & Genomics space, but the scraped website content is empty or inaccessible, preventing detailed analysis of their offerings and target market.
Data Accuracy Notice: Company information on HealthAI Central is compiled from public sources and updated regularly. While we strive for accuracy, details such as funding figures, employee counts, and product offerings may change. We recommend verifying critical information directly with the company before making business decisions.